Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQB2102 “HER2 dual antibody ADC” independently developed by the group subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing) has been included in the list of breakthrough treatment drugs by the China Drug Administration Drug Evaluation Center (CDE) for use in adult patients with unresectable or metastatic HER2 low expression (IHC 1+ or IHC 2+/ISH-) breast cancer patients who have not received chemotherapy during the recurrent or metastatic stage of the disease. This is the third breakthrough therapy recognized by TQB2102 after a new adjuvant treatment for HER2 positive early-stage breast cancer and HER2 IHC 3+ advanced colorectal cancer, further confirming its potential for widespread application in the treatment of HER2-expressing solid tumors.

Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQB2102 “HER2 dual antibody ADC” independently developed by the group subsidiary Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing) has been included in the list of breakthrough treatment drugs by the China Drug Administration Drug Evaluation Center (CDE) for use in adult patients with unresectable or metastatic HER2 low expression (IHC 1+ or IHC 2+/ISH-) breast cancer patients who have not received chemotherapy during the recurrent or metastatic stage of the disease. This is the third breakthrough therapy recognized by TQB2102 after a new adjuvant treatment for HER2 positive early-stage breast cancer and HER2 IHC 3+ advanced colorectal cancer, further confirming its potential for widespread application in the treatment of HER2-expressing solid tumors.